person · Reporting owner
Ocumension Therapeutics
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALIMERA SCIENCES INCALIM · Entity 11664 | 10% owner | April 16, 2021 | April 30, 2021 |
| EyePoint, Inc.EYEP · Entity 5702 | Director | January 11, 2024 | January 16, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALIMERA SCIENCES INC
Report date April 16, 2021 · Filed April 30, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.01 par valueSEC Table I · non-derivative | Direct | 1,144,945 |
Reported balance
Holding disclosure · report date 2021-04-16 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,144,945 F1: The reported securities are directly owned by Ocumension Therapeutics. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are directly owned by Ocumension Therapeutics.
EyePoint, Inc.
Report date January 11, 2024 · Filed January 16, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| common stockSEC Table I · non-derivative | Direct | 100,221 |
Reported balance
After 2024-01-11 transaction · row 1
1 source rowRow 1 · 2024-01-11 · Sale · Disposed 1,910,500 · Balance 100,221 F1: T+2 settlement on Jan 16 |
Filing footnotes · ownership attribution and instrument terms
F1: T+2 settlement on Jan 16
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 11, 2024 Filed Jan 16, 2024 23:55 UTC | EyePoint, Inc. EYEP · Entity 5702 | Salecommon stock | 1,910,500 | $19.45 | $37,159,225.00 |
DisclosureSEC source: 0001840315-24-000002 · primary_doc.xml · nonDerivative · entry 1 Ocumension Therapeutics · CIK 0001840315 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,221 F1 · date: T+2 settlement on Jan 16 Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 02:21 UTC | EyePoint, Inc. EYEP · Entity 5702 | Salecommon stock | 266,242 | $18.41 | $4,901,515.22 |
DisclosureSEC source: 0001840315-23-000007 · primary_doc.xml · nonDerivative · entry 2 Ocumension Therapeutics · CIK 0001840315 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,010,721 Read SEC document |
| December 05, 2023 Filed Dec 8, 2023 02:21 UTC | EyePoint, Inc. EYEP · Entity 5702 | Salecommon stock | 733,758 | $19.91 | $14,609,121.78 |
DisclosureSEC source: 0001840315-23-000007 · primary_doc.xml · nonDerivative · entry 1 Ocumension Therapeutics · CIK 0001840315 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,276,963 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.